文献速递药疹与重症皮肤不良反应皮肤肿瘤

BRAF抑制剂治疗中出现的嗜中性小汗腺炎:两例新皮肤不良事件

Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event.
PubMed 文献 · Br J Dermatol · 2017-04-16

本文报告两例IV期转移性黑色素瘤患者在使用BRAF抑制剂(达拉非尼或维莫非尼)后早期出现嗜中性小汗腺炎(NEH),表现为播散性红斑性斑块伴发热和多关节痛,组织学确诊。停药并局部使用类固醇后症状数日内消退,更换另一种BRAF抑制剂未必导致复发。NEH应纳入BRAF抑制剂诱导的嗜中性皮肤病谱。

要点

  • BRAF抑制剂治疗早期(3-4天)可出现NEH,表现为播散性红斑性斑块伴发热和多关节痛。
  • 确诊需结合临床和组织学特征,停药并局部使用类固醇后症状可迅速消退。
  • 更换另一种BRAF抑制剂是治疗选择,不一定导致NEH复发。

核心结论

  • NEH可归入BRAF抑制剂诱导的嗜中性皮肤病谱。
  • BRAF抑制剂相关NEH出现较早(3-4天),早于既往报道的药物诱导NEH(9-12天)。
  • NEH可能是小汗腺鳞状汗管化生(ESS)的早期阶段,ESS已在BRAF抑制剂治疗患者中报道。

研究设计与样本

  • 病例报告,报告两例接受BRAF抑制剂(达拉非尼或维莫非尼)治疗的IV期转移性黑色素瘤患者。

主要发现

  • 两例患者在治疗开始后早期出现播散性红斑性斑块,伴发热和多关节痛,耐受性差。
  • 组织学分析确诊NEH。
  • 停药并局部使用类固醇后数日症状消失。

关键数值与推荐

  • NEH诊断需结合临床和组织学特征。
  • BRAF抑制剂相关NEH出现时间为3-4天,早于既往药物诱导NEH的9-12天。

临床怎么用

  • 使用BRAF抑制剂的患者出现发热、多关节痛及播散性红斑性斑块时应考虑NEH。
  • 确诊后应停用可疑药物并局部使用类固醇。
  • 可考虑更换另一种BRAF抑制剂,因不一定导致NEH复发。

局限性

  • 仅基于两例病例报告,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neutrophilic eccrine hidradenitis (NEH) is a rare neutrophilic dermatosis, first described in patients undergoing chemotherapy for a malignant haemopathy. It has polymorphous clinical features and the association of both clinical and histological features is necessary to make a diagnosis. We report the first two cases of NEH in patients treated with a BRAF inhibitor (BRAFi), either dabrafenib or vemurafenib, for a stage IV metastatic melanoma. Disseminated erythematous plaques associated with fever and polyarthralgia occurred early after the initiation of treatment and were badly tolerated. Histological analyses confirmed the diagnosis of NEH. Symptoms disappeared a few days after the cessation of treatment and introduction of topical steroids. The replacement of one BRAFi with another is a therapeutic alternative as it is not necessarily associated with a relapse of NEH. NEH can be added to the spectrum of neutrophilic dermatoses induced by BRAFis. It occurs earlier (3-4 days) than previously described drug-induced NEH (9-12 days) and may be an earlier stage of eccrine squamous syringometaplasia, which has already been reported in the context of BRAFi-treated patients.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Herms F, Franck N, Kramkimel N, et al. Neutrophilic eccrine hidradenitis in two patients treated with BRAF inhibitors: a new cutaneous adverse event. Br J Dermatol. 2017. PMID: 28005274. doi:10.1111/bjd.15259

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。